Zusammenfassung
Im Fokus der Gruppe der Anxiolytika stehen weiterhin die Benzodiazepine. Auf die Risiken wird ausführlich eingegangen. Alternativen werden besprochen.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsLiteratur
de Billioti S, Moride Y, Ducruet T et al (2014) Benzodiazepine use and risk of Alzheimer’s disease: case-control study. BMJ 349:g5205
Ipser JC, Stein DJ, Hawkridge S, Hoppe L (2009) Pharmacotherapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev 3:CD005170
Yaffe K, Boustani M (2014) Benzodiazepines and risk of Alzheimer’s disease. BMJ 349:g5312
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Benkert, O., Hautzinger, M., Graf-Morgenstern, M., Anghelescu, IG. (2016). Anxiolytika. In: Benkert, O., Hautzinger, M., Graf-Morgenstern, M. (eds) Psychopharmakologischer Leitfaden für Psychologen und Psychotherapeuten. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-49092-1_8
Download citation
DOI: https://doi.org/10.1007/978-3-662-49092-1_8
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-49091-4
Online ISBN: 978-3-662-49092-1
eBook Packages: Medicine (German Language)